Abstract: Malic acid-enriched plant extracts useful as food additives are described.

Abstract: Methods for delivering therapeutic agent(s) to the central nervous system to treat a first CNS-related disease and/or condition while avoiding systemic exposure for patients having a second concurrent non-CNS-related disease and/or condition wherein the presence of the second disease and/or condition contraindicates systemic administration of the therapeutic agent(s) and/or pharmaceutical compound to treat the first disease or condition. The present invention provides these advantages by applying the therapeutic agent(s) and/or pharmaceutical composition(s) to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and administering the therapeutic agent(s) and/or pharmaceutical compound(s) directly to the CNS.

Abstract: A personal care composition is disclosed comprising a pH tuneable gellant. The pH tuneable gellant has a formula of: wherein R1 and R2 are aminofunctional end-groups; L1 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L1, R1 or R2 comprises a pH-sensitive group; wherein R5 is an aminofunctional moiety; L2 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L2 or R5 comprises a pH-sensitive group; and mixtures of [I] and [II]. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion or may comprise one or more actives or agents.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.

Abstract: A pH sensitive carrier which includes at least one pH sensitive compound selected from the group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, C27 bile acid, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof, and at least one amphipathic substance selected from the group consisting of a phosphatidylcholine having 10 to 12 carbon atoms, a polyoxyethylene sorbitan monofatty acid ester having 12 to 18 carbon atoms, a sorbitan fatty acid ester having 16 to 18 carbon atoms, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol dioleate, polyoxyethylene castor oil and ?-tocopherol, and which is capable of developing a membrane disruptive function promoting effect.

Abstract: The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.

Abstract: Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.

Abstract: A pharmaceutical composition for application in human and animals, with at least one systemically and/or locally acting, topically applicable active ingredient and with at least one phospholipid, improving the transport of the active ingredient trough the cell membrane and containing a concentration of at least 60% by weight phosphatidylcholine, referring to the phospholipid, is described. The composition shows such a liquid consistency, that it is able to be sprayed as droplets or as a foam, whereas in the composition such a phospholipid is included, that additionally contains oil in a concentration of maximum 7.5% by weight besides the at least 60% by weight phosphatidylcholine.

Abstract: The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same.

Abstract: The present invention provides preservative compositions suitable for replacing, partially or in totality, conventional preservatives in skin care and hygiene cosmetic or pharmaceutical products. The preservative formulations include an organic carboxylic acid present in a concentration from about 0.01 to about 30 wt./wt. % of the formulation, an alcohol present in a concentration from about 0.01 to about 60 wt./wt. % of the formulation. The formulations include an inorganic salt present in a concentration from about 0.01 to about 80 wt./wt. % of the formulation, and a chelating agent present in a concentration from about 0.01 to about 20 wt./wt. % of the formulation.

Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Abstract: Processes for obtaining aqueous dispersions comprising alcohols and acids obtained by hydrolysis of jojoba oil. Hydrolyzed jojoba oil products are treated by a process comprising neutralization of jojoba fatty acids with aliphatic organic amines dissolved in a co-solvent followed by the dispersion of both the neutralized fatty acids together with jojoba alcohols in an aqueous medium. The products obtained, generically named hydrolyzed jojoba oil (HJO), promote transdermal absorption and are useful vehicles for carrying a wide range of pharmaceutical and cosmetic compositions, including pharmaceutical and cosmetic compositions comprising either lipophilic or hydrophilic active principles. The HJO can also be used to produce a semisolid, self-emulsified jojoba oil (SEJO), obtained by emulsifying the HJO in jojoba oil.

Abstract: The invention provides a liquid composition containing (a) an acidic oxidant, (b) nitric acid or a salt thereof, and (c) at least one carboxylic acid selected from the group consisting of monocarboxylic acids, dicarboxylic acids, and tricarboxylic acids, or a salt thereof. The liquid composition can be used to disinfect or sterilize a subject that includes a portion made of an aluminum-based metal.

Abstract: Composition for delivery of at least one active principle at the implantation site of an implant device, including: at least one active principle, and at least a first excipient combined with the at least one active principle, wherein the at least a first excipient is selected among fatty acids with a linear or branched, saturated chain, including a number of carbon atoms between 14 and 36.

Abstract: The present invention provides an improved method of administering a medicinal, dental or nutritional agent to a non-human animal, such as a domesticated dog or cat. The method comprises mixing a liquid composition in a mixer at various speeds and pressures for a period of time; pouring the liquid composition onto a conveyor belt propelled by polymer rollers, wherein the polymer rollers allow the components to advance on the conveyor belt without adhering to the belt; evenly distributing the composition on the belt with the use of a knife; heating the composition in one or more hot-air chambers; obtaining a film comprised of the composition; cutting the film into strips; and then administering one or more of the strips to the non-human animal by placing the strip under the tongue of the animal, i.e., by sub-lingual administration.

Abstract: The present invention relates to methods comprising applying to a useful plant, the locus thereof or propagation material thereof a combination of abscisic acid and a fungicidally active compound, which fungicidally active compound is a succinate dehydrogenase inhibitor, in particular for increasing the potency of a fungicidally active compound. The invention also relates to compositions comprising abscisic acid and the fungicidally active compounds as well as seeds comprising the combinations.

Abstract: The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device. In order to increase the bio-compatibility of this device, it is provided with at least one coating. The coating contains a therapeutic agent which is comprised in a matrix that sticks to the intraluminal device. Instead of being formed by a little bio-compatible polymer, the matrix is formed by a bio-compatible oil or fat, such as cod-liver oil or olive oil. Preferably, the bio-compatible oil or fat further comprises alfa-tocopherol.

Abstract: A cosmetic composition in the form of an oil-in-water emulsion methods of using and producing cosmetic compositions is provided. The cosmetic composition includes an aqueous phase, an oil phase comprising a water-in-oil emulsifier, and an oil stabilizing component. The water-in-oil emulsifier is at concentration, by weight, of about 0.01% to about 6.0%, based upon weight of the composition. The oil stabilizing component includes one or both of an amphiphilic compound or a surfactant having an HLB of 13 or greater added to the aqueous phase. The oil stabilizing component is at a concentration, by weight, of about 0.01% to about 1.0%, based upon weight of the composition. The oil-in-water emulsion has an increased water load relative to water-in-oil emulsions without having an increased viscosity.

Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Abstract: The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.

Abstract: The present invention relates to a nanoemulsion in gel-form comprising a continuous aqueous phase and at least one dispersed oily phase, in which: the aqueous phase comprises: at least one co-surfactant including at least one polyalkoxylated chain consisting of ethylene oxide or ethylene oxide and propylene oxide units, and at least one hydrophilic agent of interest, and the oily phase comprises: at least one amphiphilic lipid, at least one solubilizing lipid consisting in a mixture of saturated fatty acid glycerides including: at least 10% by weight of C12 fatty acids, at least 5% by weight of C14 fatty acids, at least 5% by weight of C16 fatty acids, and at least 5% by weight of C18 fatty acids, at least one lipophilic agent of interest, said hydrophilic and lipophilic agents of interest being independently selected from among: a therapeutic agent, an optical agent selected from among a coloring agent, a chromophore, a fluorophore, and a physical agent selected from among a radioactive isotope and a

Abstract: A thick cleaning composition, comprising a long-chain fatty acyl acidic amino acid ester; a fatty compound of fatty acid, fatty alcohol, fatty alcohol ether or polyol fatty acid ester; a surfactant; a solvent composed of water, lower alcohol, polyol and polyol ether; and further comprising a beautifying and cleaning adjuvant for skin, eyes, teeth and hair. The cleaning composition can achieve satisfactory thick appearance when used for cleaning skin and hair, and maintain stable viscosity at different temperatures. In use, the composition can be easily daubed, and foams quickly with good foaming quality.

Abstract: The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.

Abstract: In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic acid. Also provided are pharmaceutical formulations of the encapsulants and methods of using such formulations to deliver a bioactive agent to a subject in treating or diagnosing disease in that subject.

Abstract: An object of the present invention is to provide a gel containing pyrroloquinoline quinone that is capable of easily forming a gel near room temperature and is useful even in the food sector, and a method for producing the gel. According to the present invention, there is provided a gel containing pyrroloquinoline quinone that uses pyrroloquinoline quinone itself as a gelling agent and a method for producing the gel by adding a salt of pyrroloquinoline quinone to water and subsequently adjusting the temperature or the pH to reduce solubility.

Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.

Abstract: A targeting lipid can have the formula (I) in which T4 is a targeting moiety. The targeting moiety can be chosen to favor the lipid being localized with a desired organ, tissue, cell, cell type or subtype, or organelle. The targeting moiety can include, for example, transferrin, anisamide, an RGD peptide, prostate specific membrane antigen (PSMA), fucose, an antibody, or an aptamer.

Abstract: A liquid concentrate for preserving cosmetic products which includes a combination of carboxylic component being sodium benzoate and an alcohol component being a mixture of phenoxy ethanol and benzyl alcohol, in a water, where the combination is greater than 45% by weight of the liquid concentrate.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: Compositions, comprising menthofuran and selected menthol compounds which feature improved flavour and odour properties, are provided and, in addition, the production of compositions, specifically, of emulsions with an improved storage stability.

Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.

Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Abstract: A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal. The composition includes a nonionic primary surfactant comprising an ethoxylated sorbitol oleate, a nonionic secondary surfactant, and water. The nonionic secondary surfactant is selected from the group consisting of linear ethoxylated secondary alcohols, polyoxyethylene ethers, ethoxylated sorbitan monolaurates, ethoxylated fatty acid amides and ethoxylated fatty acids that contain about 7 moles to about 26 moles of ethylene oxide and comprise from about 20 to about 36 weight percent of said composition. The water is in a sufficient amount so that the nonionic primary and secondary surfactants together with the water form a gel.

Abstract: Agrochemical concentrates having a continuous water-containing single phase, where said continuous phase also comprises an oil-based adjuvant and a hydrotrope capable of solubilising said adjuvant in said continuous phase, a process for making these concentrates and a method of using these concentrates.

Abstract: A fragrance mixture, preferably perfume oil, is described, comprising the constituents (a) (cyclopent-2-enyl ethyl acetate) and additionally (b) one or a plurality of fragrances, preferably with a floral odor note, from the group consisting of alcohols and aldehydes with a molecular weight of 210 g/mol or less and/or (c) one or a plurality of fragrances from the group consisting of ketones, ethers and esters with a molecular weight in the range from 190 g/mol through 250 g/mol.

Abstract: A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.

Abstract: Methods and compositions for producing a cellular drug release are disclosed. The method comprises: a) providing a composition comprising a therapeutically effective amount of a pharmacological agent adsorbed onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces; b) exposing the composition to a cell; c) causing entry of the mesoporous HAP into the cell and degradation of the HAP in the lysosomes of the cell and desorption of the agent from the mesoporous HAP; d) causing release of the desorbed agent from the lysosomes into the cytoplasm of the cell; and e) causing release of the desorbed agent to outside the cell. The composition comprises a) mesoporous HAP with hydrophobic surfaces; and b) a therapeutically effective amount of a pharmacological agent, adsorbed onto the hydrophobic surfaces of the mesoporous. HAP. The composition is characterized in that it constantly releases the agent in vivo for a period of at least 4 weeks.

Abstract: A plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative or a pharmaceutically acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components.

Abstract: Disclosed is a composition comprising an organogel which comprises: (a) an alkylated aromatic acid compound of the formula or mixtures thereof, wherein R1, R2, R3, R4, and R5 each, independently of the other, are hydrogen, alkyl, aryl, arylalkyl, or alkyl, provided that at least one of R1, R2, R3, R4, and R5 is —X—Rc, wherein —X— is a linking group between Rc and the aromatic group and Rc is alkyl; and (b) an organic liquid.

Abstract: The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.

Abstract: A composition provides an isotonic nasal irrigation solution with pH less than about 7.0. The composition may be formed of a salt and a pH buffer and may include an additive. The composition may be mixed with water to form the solution. The composition may aid in the treatment of various nasal or sinus disorders such as, for example, dryness, rhinitis, and sinusitis. The isotonic irrigation solution may also aid in the removal of contaminants from the sinus and nasal cavities such as blood, mucus, dirt, pollen, allergens, viruses, and bacterial. The composition may be liquid or dry.

Abstract: The invention relates to an anti-dandruff shampoo comprising:—a) from 0.1 to 5 wt. % of an anti-dandruff zinc salt; b) from 1 to 8 wt. % of an alkyl glycinate and/or alkyl carboxyglycinate; c) from 2 to 16 wt. % of an alkyl sulphate and/or an ethoxylated alkyl sulfate anionic surfactant; and, d) from 1 to 10 wt. % of a fatty acyl isethionate product which product comprises 40 to 80 wt. % fatty acyl isethionate and 15 to 50 wt. % free fatty acid and/or fatty acid salt and to the use of a surfactant system comprising components b) to d) to provide an improvement to the skin stratum corneum barrier.

Abstract: There are provided a stabilized polyphenol solution which is applicable as various contact lens solutions and has high lens compatibility and safety, and further also a method for stabilizing such a polyphenol solution. At least one inorganic salt-free buffer is contained in a concentration of 0.001-5% by weight in an aqueous solution containing at least one polyphenol, at least one polyol is further contained therein in a concentration of 0.01-5% by weight to prepare a solution so as to contain no inorganic salt, and the pH of the solution is adjusted to 7.3 or less.

Abstract: A lotion having an emollient and an immobilizing agent. The emollient is derived from a renewable resource and having a bio-based content of from about 10% to about 100% using ASTM D6866-10, method B and the immobilizing agent selected from the group consisting of C14-C60 fatty alcohols, C14-C60 fatty acids, C14-C60 fatty alcohol ethoxylates having an average degree of ethoxylation ranging from about 2 to about 110, waxes and mixtures thereof. Absorbent articles comprising said lotions are also provided for herein.

Abstract: The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.

Abstract: Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A? and one or more hydrophobic anchors covalently linked to the scaffold. The A and A? compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.

Abstract: A peptide attached to a nanoparticles (such as quantum dots) selectively directs the nanoparticles to neurons in a tissue or organism.

Abstract: Provided are methods and compositions useful for treating/aches and/or pains. The compositions comprise an herbal therapeutic agent and an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane.

Abstract: The present invention provides compositions that may be an aqueous insecticide containing at least one surfactant, such as for instance, sodium lauryl sulfate, at least one preservative, such as for instance, a potassium salt or sodium chloride, a nutrient source, such as for instance a yeast, an organic acid capable of lowering the pH of the aqueous insecticide, such as for instance citric acid, a fragrance, such as for instance geranium oil, and water. The aqueous insecticide may be designed to more efficiently kill and thereby control populations of species of Cimex, such as, for instance, Cimex lectularius.